Scholarlink

Introduction <p>Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) impact quality of life. Medication persistence is a key determinant of long-term effectiveness in chronic inflammatory diseases. This study evaluated treatment persistence, function, and program satisfaction among Canadian patients with RA, PsA, and axSpA receiving upadacitinib enrolled in the AbbVie Care patient support program (PSP).</p> Methods <p>Data were collected from adults with RA, PsA, or axSpA enrolled in the Canadian PSP between January 2020 and July 2025. Demographic characteristics, first prescription fill rates, medication persistence, Health Assessment Questionnaire Disability Index (HAQ-DI) scores, and patient satisfaction with the PSP (subset of RA patients) were assessed.</p> Results <p>A total of 16,075 patients enrolled in the PSP were assessed (RA: <i>N</i> = 11,449; PsA: <i>N</i> = 2751; axSpA <i>N</i> = 1875). Over 90% of all patients filled their first upadacitinib prescription within 7&#xa0;days. Among patients with RA, medication persistence was 73%, 63%, 56%, and 51% at 12, 24, 36, and 48 months, respectively. In PsA, persistence was 68%, 54%, and 47% at 12, 24, and 36&#xa0;months, and with axSpA, persistence was 63% and 50% at 12&#xa0;and 24 months. Patients with RA had a mean reduction from baseline in HAQ-DI of −&#xa0;0.40 (<i>N</i> = 777; SD: 0.77; <i>P</i> &lt; .001) and most patients (62%) achieved minimal clinically important difference (MCID; improvement ≥ 0.22[RA] or ≥ 0.35[PsA]), with 28% having normative values (HAQ-DI ≤ 0.25). Among patients with PsA, the mean reduction from baseline in HAQ-DI was −&#xa0;0.65 (<i>N</i> = 153; SD: 0.66; <i>P</i> &lt; 0.001); 73% of patients achieved MCID and 26% had normative values. Among 200 RA patients surveyed, nearly 90% were extremely/very satisfied with the PSP.</p> Conclusions <p>High first prescription fill and long-term persistence rates were observed in patients with RA, PsA, and axSpA enrolled in a single national PSP, along with substantial improvements in physical function.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-World Upadacitinib Persistence and Clinical Outcomes Among Canadian Patients with Inflammatory Arthritis from a Patient Support Program: The UPRAISE Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月23日

查看全文
  • Janet E. Pope,
  • Jayeshkumar Patel,
  • Christopher D. Saffore,
  • Siran Fang,
  • Al Rasymas,
  • Dalinda Liazoghli,
  • Olga Ziouzina

摘要

Introduction

Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) impact quality of life. Medication persistence is a key determinant of long-term effectiveness in chronic inflammatory diseases. This study evaluated treatment persistence, function, and program satisfaction among Canadian patients with RA, PsA, and axSpA receiving upadacitinib enrolled in the AbbVie Care patient support program (PSP).

Methods

Data were collected from adults with RA, PsA, or axSpA enrolled in the Canadian PSP between January 2020 and July 2025. Demographic characteristics, first prescription fill rates, medication persistence, Health Assessment Questionnaire Disability Index (HAQ-DI) scores, and patient satisfaction with the PSP (subset of RA patients) were assessed.

Results

A total of 16,075 patients enrolled in the PSP were assessed (RA: N = 11,449; PsA: N = 2751; axSpA N = 1875). Over 90% of all patients filled their first upadacitinib prescription within 7 days. Among patients with RA, medication persistence was 73%, 63%, 56%, and 51% at 12, 24, 36, and 48 months, respectively. In PsA, persistence was 68%, 54%, and 47% at 12, 24, and 36 months, and with axSpA, persistence was 63% and 50% at 12 and 24 months. Patients with RA had a mean reduction from baseline in HAQ-DI of − 0.40 (N = 777; SD: 0.77; P < .001) and most patients (62%) achieved minimal clinically important difference (MCID; improvement ≥ 0.22[RA] or ≥ 0.35[PsA]), with 28% having normative values (HAQ-DI ≤ 0.25). Among patients with PsA, the mean reduction from baseline in HAQ-DI was − 0.65 (N = 153; SD: 0.66; P < 0.001); 73% of patients achieved MCID and 26% had normative values. Among 200 RA patients surveyed, nearly 90% were extremely/very satisfied with the PSP.

Conclusions

High first prescription fill and long-term persistence rates were observed in patients with RA, PsA, and axSpA enrolled in a single national PSP, along with substantial improvements in physical function.